Core Viewpoint - The announcement highlights the results of various clinical trials for LuX-Valve Plus, JensClip, and Ken-Valve, showcasing advancements in transcatheter heart valve technologies presented at the TCT2025 conference [1] Group 1: Clinical Trial Results - LuX-Valve Plus's global multicenter clinical trial (TRINITY) reported six-month follow-up results for transcatheter tricuspid valve replacement (TTVR) [1] - JensClip's one-year follow-up results for transcatheter mitral valve repair (TMVr) were shared, along with evidence of its effectiveness in challenging cases [1] - Ken-Valve's one-year follow-up results for transcatheter aortic valve replacement (TAVR) were also presented, including outcomes in challenging case applications [1] Group 2: Conference Presentation - The results were presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT2025) conference held in San Francisco [1]
健世科技-B多产品组合LuX-Valve Plus TRINITY研究、JensClip及 Ken-Valve临床效果于美国TCT 2025发布，成果瞩目